Forx Therapeutics AG presented data on their PARG inhibitor – FORX-428 – for the treatment of cancer. FORX-428 is a highly potent, selective and orally bioavailable PARG inhibitor that showed strong and reversible binding to the catalytic domain of the human PARG enzyme.
Forx Therapeutics AG has discovered new bicyclo heteroaryl poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Shanghai Tyk Medicines Co. Ltd. and Tyk Medicines Inc. have identified poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Nanjing Synnocare Pharmaceutical Technology Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yingli Pharmaceutical Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
DNA damage repair enzymes are interesting targets in cancer, since genomic instability and DNA repair defects are important cancer cell hallmarks. Poly (ADP-ribose) glycohydrolase (PARG) is the dominant eliminator of PARylation in the cell, the activity of which prevents excessive accumulation of PARylation, and promotes the dissociation of repair proteins, as well as ensuring the smooth completion of DNA repair process.
